
Sign up to save your podcasts
Or


For decades, the best drug therapies for treating depression, like SSRIs, have been based on the idea that depressed brains don’t have enough of the neurotransmitter serotonin. Yet for almost as long, it’s been clear that simplistic theory is wrong. Recent research into the true causes of depression is finding clues in other neurotransmitters and the realization that the brain is much more adaptable than scientists once imagined. Treatments for depression are being reinvented by drugs like ketamine that can help regrow synapses, which can in turn restore the right brain chemistry and improve whole body health.
In this episode, John Krystal, a neuropharmacologist at the Yale School of Medicine, tells Steve Strogatz about the new findings in mental health research that are revolutionizing psychiatric medication.
By Steven Strogatz, Janna Levin and Quanta Magazine4.9
482482 ratings
For decades, the best drug therapies for treating depression, like SSRIs, have been based on the idea that depressed brains don’t have enough of the neurotransmitter serotonin. Yet for almost as long, it’s been clear that simplistic theory is wrong. Recent research into the true causes of depression is finding clues in other neurotransmitters and the realization that the brain is much more adaptable than scientists once imagined. Treatments for depression are being reinvented by drugs like ketamine that can help regrow synapses, which can in turn restore the right brain chemistry and improve whole body health.
In this episode, John Krystal, a neuropharmacologist at the Yale School of Medicine, tells Steve Strogatz about the new findings in mental health research that are revolutionizing psychiatric medication.

301 Listeners

832 Listeners

558 Listeners

521 Listeners

252 Listeners

1,061 Listeners

77 Listeners

4,153 Listeners

2,337 Listeners

449 Listeners

499 Listeners

251 Listeners

318 Listeners

33 Listeners

391 Listeners

509 Listeners